2022
Factors associated with HIV testing and treatment among young Black MSM and trans women in three jail systems
Antos N, Flores R, Harawa N, Del Vecchio N, Issema R, Fujimoto K, Khanna A, Di Paola A, Schneider J, Hotton A. Factors associated with HIV testing and treatment among young Black MSM and trans women in three jail systems. AIDS Care 2022, 35: 123-130. PMID: 35848452, PMCID: PMC10359835, DOI: 10.1080/09540121.2022.2094312.Peer-Reviewed Original ResearchConceptsHIV testingViral suppressionHigher oddsMultivariable logistic regressionYoung Black MSMFull multivariable modelDuration of incarcerationMultivariable modelLower oddsBinge drinkingBlack MSMTransgender womenLogistic regressionJail systemOddsBlack menBMSMWomenMenTreatmentTrans womenLos AngelesProtective custodyLevel factorsIncarcerationGender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisorders
2020
Covariates of hazardous alcohol use among sexual and gender minorities in Texas: Identifying the most vulnerable
Wilkerson J, Di Paola A, McCurdy S, Schick V. Covariates of hazardous alcohol use among sexual and gender minorities in Texas: Identifying the most vulnerable. Addictive Behaviors 2020, 105: 106327. PMID: 32044679, DOI: 10.1016/j.addbeh.2020.106327.Peer-Reviewed Original ResearchConceptsHazardous drinkersHistory of incarcerationHazardous drinkingLogistic regression modelsMultivariate logistic regression modelMultiple logistic regression modelNon-hazardous drinkersHazardous alcohol useRegression modelsCriminal justice involvementAlcohol useMental healthSubstance useDrinkersDrinkingPrevalenceJustice involvementGender minority personsDepressionCovariatesSGM adolescentsMarijuanaOnline surveyMinority personsOpioids
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesSubstance Use, Mental Health, HIV Testing, and Sexual Risk Behavior Among Men Who Have Sex With Men in the State of Maharashtra, India.
Wilkerson J, Di Paola A, Rawat S, Patankar P, Rosser B, Ekstrand M. Substance Use, Mental Health, HIV Testing, and Sexual Risk Behavior Among Men Who Have Sex With Men in the State of Maharashtra, India. AIDS Education And Prevention 2018, 30: 96-107. PMID: 29688773, PMCID: PMC6214349, DOI: 10.1521/aeap.2018.30.2.96.Peer-Reviewed Original ResearchConceptsIllicit substance useSubstance usePolysubstance useHazardous drinkingIntimate partner violenceSexual partnersCondomless anal sexMental health servicesPublic health interventionsSexual risk behaviorsHIV testingOverall prevalenceAnal sexHealth servicesHealth interventionsRisk behaviorsIllicit substancesMental healthMenSexPartner violenceDrinkingParticipantsOnline surveyHIV
2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic features
2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentPlacebo-controlled trialXR-NTXAgonist treatmentOpioid dependenceTreatment outcomesPoor HIV treatment outcomesOpioid treatment outcomesOpioid-dependent prisonersExtended-release naltrexoneHIV treatment outcomesHIV transmission riskEvidence-based treatmentsCriminal justice settingsEarly acceptabilityStudy medicationFirst injectionStudy acceptabilityHIVTotal referralsJail detaineesCommunity settingsTransmission riskDrug relapseHigh internal validityAn evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone